Literature DB >> 11128688

Hydroxychloroquine neuromyotoxicity.

M Stein1, M J Bell, L C Ang.   

Abstract

Hydroxychloroquine (HCQ) is commonly prescribed for treatment of inflammatory arthritis. The most frequently observed serious side effect is retinal toxicity; however, case reports have described HCQ induced neuromyotoxicity. We describe a case of HCQ neuromyotoxicity and a literature review from 1965 to September 1998 using Medline and Embase. Including our patient, there are 10 reported cases of HCQ neuromyotoxicity. Muscle biopsy consistently reveals curvilinear bodies and muscle fiber atrophy with vacuolar changes. Most cases manifest as insidious onset proximal myopathy that may be associated with peripheral neuropathy and cardiac myotoxicity. Resolution of symptoms is slow after discontinuation of therapy and may be incomplete. Possible predisposing factors include Caucasian race and concomitant renal failure. Patients treated with HCQ who develop a proximal myopathy, cardiomyopathy, or neuropathy, especially in the setting of worsening renal function, should be evaluated for possible HCQ neuromyotoxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11128688

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  40 in total

Review 1.  The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.

Authors:  M Jallouli; D Saadoun; B Eymard; G Leroux; J Haroche; D Le Thi Huong; C De Gennes; C Chapelon; O Benveniste; B Wechsler; P Cacoub; Z Amoura; J C Piette; N Costedoat-Chalumeau
Journal:  J Neurol       Date:  2011-12-08       Impact factor: 4.849

2.  Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.

Authors:  Clotilde Chatre; François Roubille; Hélène Vernhet; Christian Jorgensen; Yves-Marie Pers
Journal:  Drug Saf       Date:  2018-10       Impact factor: 5.606

Review 3.  Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2020-04-08       Impact factor: 8.262

4.  Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients.

Authors:  E Casado; J Gratacós; C Tolosa; J M Martínez; I Ojanguren; A Ariza; J Real; A Sanjuán; M Larrosa
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

Review 5.  Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.

Authors:  Eva Schrezenmeier; Thomas Dörner
Journal:  Nat Rev Rheumatol       Date:  2020-02-07       Impact factor: 20.543

6.  Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.

Authors:  Jutta G Richter; Arnd Becker; Benedikt Ostendorf; Christof Specker; G Stoll; E Neuen-Jacob; Matthias Schneider
Journal:  Rheumatol Int       Date:  2003-05-09       Impact factor: 2.631

Review 7.  Management of autoimmune skin disorders in the elderly.

Authors:  Wei Jing Loo; Nigel P Burrows
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing.

Authors:  Thomas Khoo; Sophia Otto; Caroline Smith; Barbara Koszyca; Sue Lester; Peter Blumbergs; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2016-09-14       Impact factor: 2.980

9.  Blueberry opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activation protein kinase.

Authors:  Yuyan Zhu; Paula C Bickford; Paul Sanberg; Brian Giunta; Jun Tan
Journal:  Rejuvenation Res       Date:  2008-10       Impact factor: 4.663

10.  Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France.

Authors:  Antoine Pariente; Paul Avillach; Francesco Salvo; Frantz Thiessard; Ghada Miremont-Salamé; Annie Fourrier-Reglat; Françoise Haramburu; Bernard Bégaud; Nicholas Moore
Journal:  Drug Saf       Date:  2012-10-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.